Charles Schwab Investment Management Inc. Has $50.41 Million Stock Position in Repligen Corporation $RGEN

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Repligen Corporation by 4.8%, purchasing an additional 18,250 shares, bringing its total ownership to approximately $50.4 million.
• Repligen's stock is currently valued at $124.35, with a market cap of $7 billion and a significant percentage (97.64%) of shares owned by institutional investors.
• The company's recent earnings report showed a 14.8% year-over-year revenue increase but fell short of EPS estimates, reporting $0.37 versus a consensus of $0.40.

Charles Schwab Investment Management Inc. grew its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 4.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 396,150 shares of the biotechnology company's stock after acquiring an additional 18,250 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.71% of Repligen worth $50,406,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Raiffeisen Bank International AG bought a new stake in Repligen in the 4th quarter valued at $29,000. Itau Unibanco Holding S.A. bought a new stake in shares of Repligen in the fourth quarter valued at about $40,000. Signaturefd LLC grew its position in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after buying an additional 128 shares in the last quarter. Center for Financial Planning Inc. increased its stake in Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 193 shares during the period. Finally, UMB Bank n.a. increased its stake in Repligen by 99.4% during the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 332 shares during the period. Institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on RGEN. Royal Bank Of Canada raised their price objective on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 30th. Stephens raised Repligen to an "overweight" rating and set a $160.00 target price for the company in a research report on Tuesday, July 22nd. Evercore ISI decreased their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Finally, Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a report on Tuesday, April 29th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Repligen currently has an average rating of "Moderate Buy" and a consensus target price of $169.45.

Insider Buying and Selling at Repligen

In related news, Director Martin D. Madaus acquired 1,800 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the transaction, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Repligen Price Performance

NASDAQ RGEN traded down $1.71 on Wednesday, hitting $121.79. 202,783 shares of the company were exchanged, compared to its average volume of 776,837. The firm has a 50 day moving average of $122.16 and a two-hundred day moving average of $132.13. The company has a market cap of $6.85 billion, a P/E ratio of -486.74, a P/E/G ratio of 2.28 and a beta of 1.05. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the previous year, the business posted $0.40 EPS. The company's revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities analysts predict that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.